Literature DB >> 11487511

Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs.

J Keeble1, O A Al-Swayeh, P K Moore.   

Abstract

The effect of several nitric oxide releasing-non-steroidal anti-inflammatory drugs (NO-NSAID) and nitroprednisolone on blood vessel relaxation in vitro and in vivo was studied. Nitroflurbiprofen (NOF; EC(50), 688.8+/-93.8 microM), nitroaspirin (NOA; EC(50), 57.9+/-6.5 microM), nitroparacetamol (NOPARA; EC(50), 71.5+/-14.6 microM) and nitroprednisolone (EC(50), 15.1+/-1.4 microM) caused concentration-related relaxation of noradrenaline (NA)-contracted rat aortic rings. All NO releasing compounds tested were approximately three orders of magnitude less potent than sodium nitroprusside (SNP, EC(50), 35.7+/-3.5 nM). The vasorelaxant effect of NOF and NOPARA in the rat aorta was potentiated by zaprinast (5 microM) and reduced by ODQ (5 microM). Flurbiprofen and paracetamol (100 microM) caused minimal (<10%) relaxation of the rat aorta and did not affect the response to SNP. The effect of NOF was unchanged in the presence of L-NAME (100 microM; EC(30), 181.8+/-35.1 microM cf. EC(30), 125.1+/-17.0 microM, P>0.05) but increased by removal of the endothelium (EC(30), 164.3+/-26.3 microM cf. EC(50), 688.8+/-93.8 microM, P<0.05). NOF (0.1 - 50 microM) produced a small but not concentration-related vasodilation of the NA-preconstricted (i.e. "high tone") perfused rat mesentery preparation (cf. SNP, EC(30), 4.4+/-0.7 microM). In contrast, NOF (1 - 100 microM) produced concentration-related vasodilation of the "high tone" perfused rat kidney with an EC(50) of 33.1+/-4.4 microM. Neither NOF (74 mg kg(-1), i.p.) nor NOA (91.9 mg kg(-1), i.p.) nor equimolar doses of flurbiprofen (50 mg kg(-1), i.p.) or aspirin (50 mg kg(-1), i.p.) affected mean arterial blood pressure (MAP) or heart rate (HR) of pentobarbitone-anaesthetized rats over a 1 h period. NO-NSAID relax blood vessels in vitro by an NO-dependent mechanism. The absolute vasorelaxant effect of NO releasing drug varies greatly with the choice of compound and between blood vessel preparations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487511      PMCID: PMC1572867          DOI: 10.1038/sj.bjp.0704161

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

Review 1.  NO-aspirins: a class of new anti-inflammatory and antithrombotic agents.

Authors:  P del Soldato; R Sorrentino; A Pinto
Journal:  Trends Pharmacol Sci       Date:  1999-08       Impact factor: 14.819

2.  21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties.

Authors:  M Paul-Clark; P Del Soldato; S Fiorucci; R J Flower; M Perretti
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  The effect of aspirin and two nitric oxide donors on the infarcted heart in situ.

Authors:  T Yamamoto; N R Kakar; E R Vina; P E Johnson; R J Bing
Journal:  Life Sci       Date:  2000-07-07       Impact factor: 5.037

4.  The pharmacology of a new nitric oxide donor: B-NOD.

Authors:  R J Bing; T Yamamoto; H Kim; R H Grubbs
Journal:  Biochem Biophys Res Commun       Date:  2000-08-28       Impact factor: 3.575

5.  A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin.

Authors:  O A al-Swayeh; R H Clifford; P del Soldato; P K Moore
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

6.  Endothelium-derived relaxing factor and the effects of acetylcholine and histamine on resistance blood vessels.

Authors:  R Bhardwaj; P K Moore
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

7.  A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats.

Authors:  S N Elliott; W McKnight; G Cirino; J L Wallace
Journal:  Gastroenterology       Date:  1995-08       Impact factor: 22.682

8.  Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivative, nitroflurbiprofen.

Authors:  S Mariotto; M Menegazzi; A Carcereri de Prati; L Cuzzolin; A Adami; H Suzuki; G Benoni
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat.

Authors:  J L Wallace; B Reuter; C Cicala; W McKnight; M B Grisham; G Cirino
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

10.  L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro.

Authors:  P K Moore; O A al-Swayeh; N W Chong; R A Evans; A Gibson
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

View more
  4 in total

Review 1.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

2.  Nitric oxide-releasing flurbiprofen reduces formation of proinflammatory hydrogen sulfide in lipopolysaccharide-treated rat.

Authors:  Farhana Anuar; Matthew Whiteman; Jia Ling Siau; Shing Erl Kwong; Madhav Bhatia; Philip K Moore
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

3.  Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy.

Authors:  Gail D Thomas; Jianfeng Ye; Claudio De Nardi; Angela Monopoli; Ennio Ongini; Ronald G Victor
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

Review 4.  Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.

Authors:  Isla S Mackenzie; Daniel Rutherford; Thomas M MacDonald
Journal:  Arthritis Res Ther       Date:  2008-10-17       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.